MNG268
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.355
- OXIDATIVE_PHOSPHORYLATION+0.315
- NOTCH_SIGNALING+0.294
- PROTEIN_SECRETION+0.227
- MYC_TARGETS_V1+0.206
- UV_RESPONSE_DN+0.202
- UV_RESPONSE_UP+0.202
- WNT_BETA_CATENIN_SIGNALING+0.176
- APICAL_JUNCTION+0.174
- UNFOLDED_PROTEIN_RESPONSE+0.173
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.432
- IL6_JAK_STAT3_SIGNALING-0.356
- ALLOGRAFT_REJECTION-0.352
- TNFA_SIGNALING_VIA_NFKB-0.299
- INTERFERON_GAMMA_RESPONSE-0.295
- INFLAMMATORY_RESPONSE-0.263
- COMPLEMENT-0.261
- HYPOXIA-0.216
- SPERMATOGENESIS-0.197
- APOPTOSIS-0.194
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 131546 | EPN | EPN Tumor | 0.831 |
| 2 | MNG147 | — | — | 0.790 |
| 3 | MNG239 | — | — | 0.785 |
| 4 | DRR168566 | — | — | 0.781 |
| 5 | SJEPD003_D.RNA-Seq | EPN | Supratentorial EPN | 0.774 |
| 6 | 167869B6-9620-445E-BA77-B6F95A6463F5 | — | — | 0.772 |
| 7 | 0D8C7EC1-9BFB-44A1-8AF8-05D2A6BBE0F9 | — | — | 0.769 |
| 8 | MDT-AP-0417 | Med | Medulloblastoma | 0.767 |
| 9 | E3818BAA-BA28-4CE4-A745-BB3692883888 | — | — | 0.760 |
| 10 | 70b9dbcc-882d-4c90-a286-c94169e1d418 | — | — | 0.758 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 17 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.355 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.315 | Remibrutinib | — uncovered |
| NOTCH_SIGNALING | 0.294 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.227 | Remibrutinib | — uncovered |
| MYC_TARGETS_V1 | 0.206 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.202 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.202 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.176 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.174 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.173 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.166 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.161 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.092 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.086 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.045 | Inavolisib | — uncovered |
| PEROXISOME | 0.018 | Idelalisib | — uncovered |
| HEME_METABOLISM | 0.003 | Temsirolimus | — uncovered |